Centogene announced data from the company’s Rostock International Parkinson’s Disease, or ROPAD, Study revealing the genetic factors and prevalence of Parkinson’s disease, or PD. The findings from this study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and GBA1. The data was published in Brain in a paper titled, “Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTG:
- Centogene Unveils Genetic Link in Parkinson’s Disease
- CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
- Centogene and C-Path Strengthen Drug Development Alliance
- Centogene & C-Path team on LD research and drug development
- C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development